Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Exploring Undiscovered Gems In Europe March 2025

In This Article:

As the pan-European STOXX Europe 600 Index continues its streak of weekly gains, buoyed by encouraging company results and defense stock rallies, the European market landscape presents intriguing opportunities despite mixed economic signals from major economies like Germany and France. In this dynamic environment, identifying promising stocks often involves looking for companies that demonstrate resilience and potential for growth amid broader market uncertainties.

Top 10 Undiscovered Gems With Strong Fundamentals In Europe

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Ovostar Union

0.01%

10.19%

49.85%

★★★★★★

Martifer SGPS

123.58%

-2.38%

5.61%

★★★★★★

Bahnhof

NA

8.39%

14.20%

★★★★★★

La Forestière Equatoriale

NA

-58.49%

45.78%

★★★★★★

Moury Construct

2.93%

10.28%

30.93%

★★★★★☆

Caisse Regionale de Credit Agricole Mutuel Toulouse 31

14.94%

0.59%

5.95%

★★★★★☆

Evergent Investments

5.49%

1.15%

8.81%

★★★★★☆

Infinity Capital Investments

NA

9.92%

22.16%

★★★★★☆

ABG Sundal Collier Holding

0.61%

-1.57%

-8.96%

★★★★☆☆

Practic

NA

3.63%

6.85%

★★★★☆☆

Click here to see the full list of 365 stocks from our European Undiscovered Gems With Strong Fundamentals screener.

Here we highlight a subset of our preferred stocks from the screener.

Pharmanutra

Simply Wall St Value Rating: ★★★★★☆

Overview: Pharmanutra S.p.A. is a pharmaceutical and nutraceutical company that focuses on researching, designing, developing, and marketing nutritional supplements and medical devices across Italy, Europe, the Middle East, South America, the Far East, and other international markets with a market cap of €556.30 million.

Operations: Pharmanutra generates revenue primarily through its operations in Italy (€68.35 million) and international markets (€38.40 million), with a smaller contribution from Akern (€5.49 million).

Pharmanutra, a notable player in the personal products sector, has demonstrated impressive financial health with its earnings growing 36% over the past year, outpacing the industry average of 14%. The company boasts a robust EBIT coverage for interest payments at 40.7 times, indicating strong profitability. Despite an increase in its debt-to-equity ratio from 19.2% to 39.6% over five years, Pharmanutra maintains more cash than total debt and is free cash flow positive. With earnings projected to grow annually by 18%, it seems poised for continued expansion within its niche market segment.

BIT:PHN Debt to Equity as at Mar 2025
BIT:PHN Debt to Equity as at Mar 2025

Assystem

Simply Wall St Value Rating: ★★★★★★